

November 13, 2017



## Actinium Pharmaceuticals to Host Webcast to Introduce New Clinical Initiative in Collaboration with Leading Hematologist Dr. Gail Roboz

- Dr. Gail Roboz, Director of the Leukemia Program and Professor of Medicine at Weill Cornell Medical College and NewYork-Presbyterian will introduce the planned clinical initiative on the webcast

- Webcast to be held on Tuesday, December 5, 2017 at 8 AM ET

NEW YORK, Nov. 13, 2017 (GLOBE NEWSWIRE) -- **Actinium Pharmaceuticals, Inc.** (NYSE American:ATNM) ("**Actinium**" or "**the Company**"), a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for safer myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells, announced today that the Company will host a webcast to announce and detail a new clinical initiative. The planned clinical trial will be lead by Dr. Gail Roboz, Director of the Leukemia Program and Professor of Medicine at Weill Cornell Medical College and NewYork-Presbyterian. Dr. Roboz and company officials will provide an overview, including the rationale, targeted disease indication, patient population, timing and other details on the webcast. Details for the Company's webcast are below:

Date: December 5, 2017

Time: 8:00 AM ET

Webcast Link: <https://onecast.thinkpragmatic.com/ses/b9Fgmq01hWm-5D2yNB3B3w~~>

Dial-In: US (646) 402-9440

Toll Free Dial-in U.S./Canada: US (646) 402-9440

Sandesh Seth, Actinium's Chairman and CEO said, "It is an honor to be working with a renowned hematologist like Dr. Roboz to develop and advance therapies for patients using Actinium's technology. Dr. Roboz's interest in our technology furthers our belief that our targeted radiotherapy technology has the ability to improve patient outcomes, particularly in difficult niche indications where standard approaches fail to deliver a meaningful clinical benefit. In 2016, we committed to launching our third clinical program, which was a milestone we met well ahead of schedule when we announced Actimab-M in early 2017. This year, we signaled our intention to unveil an additional program for 2018. We are excited to continue the trend of exceeding milestones with this fourth clinical program that will join lomab-B, Actimab-A and Actimab-M in our growing armamentarium of product candidates that can potentially enable safer myeloablation prior to a bone marrow transplant and improve

outcomes for patients with blood cancers.”

### **About Actinium Pharmaceuticals, Inc.**

Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for safer myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. We are currently conducting clinical trials for our three product candidates, lomab-B, Actimab-A and Actimab-M, as well as performing research on other potential drug candidates utilizing our proprietary actinium-225 technology platform. Our most advanced product candidate, lomab-B, is comprised of an anti-CD45 monoclonal antibody labeled with iodine-131. We are currently conducting a pivotal Phase 3 trial of lomab-B for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. A bone marrow transplant is a potentially curative treatment option for patients with AML and other blood cancers including leukemias, lymphomas and multiple myeloma as well as certain blood disorders. Upon successful completion of our Phase 3 clinical trial for lomab-B we intend to submit this candidate for marketing approval in the U.S. and European Union. Our most advanced alpha-particle based therapy, Actimab-A, is an anti-CD33 monoclonal antibody conjugated with the alpha-particle actinium-225 (Ac-225). Actimab-A is currently in a Phase 2 clinical trial for patients over the age of 60 who are newly diagnosed with AML and ineligible for standard induction chemotherapy. Actimab-M, our third product candidate, is the same anti-CD33 monoclonal antibody conjugated to Ac-225 administered at a different dose and dosing regimen. Actimab-M, is being studied in a Phase 1 trial for patients with refractory multiple myeloma. We expect our Actinium-225 Technology Platform will generate additional drug candidates that we will progress in clinical trials ourselves and or out-license. More information available at [www.actiniumpharma.com](http://www.actiniumpharma.com) and Twitter feed @ActiniumPharma, [www.twitter.com/actiniumpharma](https://www.twitter.com/actiniumpharma).

### **Forward-Looking Statements for Actinium Pharmaceuticals, Inc.**

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

### **Contact:**

#### **Actinium Pharmaceuticals, Inc.**

Steve O'Loughlin

Principal Financial Officer

[soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com)

Investor Relations

Marek Ciszewski, J.D.

949.574.3860

ATNM@liolios.com

Source: Actinium Pharmaceuticals